10/14/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Parnate Amdipharm

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Tranylcypromin

Tranylcypromin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Reprotox. Tranylcypromine. Micromedex [www]. [cited 2025-08-19].

  2. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.

  3. Kennedy D, Webster WS, Hill M, Ritchie HE. Abnormal pregnancy outcome associated with high-dose maternal tranylcypromine therapy: Case report and literature review. Reprod Toxicol. 2017;69:146-149.

  4. Abboxia. Abbonate. Produktresumé. Läkemedelsverket [www]. [updated 2024-04-16, cited 2025-08-19].

  5. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293-308.

  6. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry. 2013;47(11):1002-12.

  7. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N,Pedersen LH. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. BJOG. 2021 Nov;128(12):1949-1957.

  8. Rommel AS, Momen NC, Molenaar NM, Agerbo E, Bergink V, Munk-Olsen T et al. Antidepressant use during pregnancy and risk of adverse neonatal outcomes: A comprehensive investigation of previously identified associations. Acta Psychiatr Scand. 2022;145(6):544-556.

  9. Kautzky A, Slamanig R, Unger A, Höflich A. Neonatal outcome and adaption after in utero exposure to antidepressants: A systematic review and meta-analysis. Acta Psychiatr Scand. 2022;145(1):6-28.

  1. Reprotox. Tranylcypromine. Micromedex [www]. [cited 2025-08-19].
  2. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.
  3. Kennedy D, Webster WS, Hill M, Ritchie HE. Abnormal pregnancy outcome associated with high-dose maternal tranylcypromine therapy: Case report and literature review. Reprod Toxicol. 2017;69:146-149.
  4. Abboxia. Abbonate. Produktresumé. Läkemedelsverket [www]. [updated 2024-04-16, cited 2025-08-19].
  5. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293-308.
  6. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry. 2013;47(11):1002-12.
  7. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N,Pedersen LH. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. BJOG. 2021 Nov;128(12):1949-1957.
  8. Rommel AS, Momen NC, Molenaar NM, Agerbo E, Bergink V, Munk-Olsen T et al. Antidepressant use during pregnancy and risk of adverse neonatal outcomes: A comprehensive investigation of previously identified associations. Acta Psychiatr Scand. 2022;145(6):544-556.
  9. Kautzky A, Slamanig R, Unger A, Höflich A. Neonatal outcome and adaption after in utero exposure to antidepressants: A systematic review and meta-analysis. Acta Psychiatr Scand. 2022;145(1):6-28.